Showing results (241-250 of 254) with videos related to

Sort By:
Pageof 26
Vaccine|December 11, 1999
Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97C Buxton Bridges, K Fukuda, R C Holman, et al.
Antimicrobial Agents and Chemotherapy|October 9, 2013
Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox)Eric M Mucker, Arthur J Goff, Joshua D Shamblin, et al.
Oncotarget|February 8, 2019
Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic driftMonique M P Speirs, Adam C Swensen, Tsz Y Chan, et al.
The Pediatric Infectious Disease Journal|September 23, 2000
The incidence of Kawasaki syndrome in West Coast health maintenance organizationsE D Belay, R C Holman, M J Clarke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2008
Pathology and pathogenesis of fatal Bordetella pertussis infection in infantsChristopher D Paddock, Gary N Sanden, James D Cherry, et al.
The Pediatric Infectious Disease Journal|August 1, 1998
Epidemiology of diarrheal disease among children enrolled in four West Coast health maintenance organizations. Vaccine Safety Datalink TeamU D Parashar, R C Holman, J S Bresee, et al.
The New England Journal of Medicine|June 25, 1981
Kawasaki syndrome: description of two outbreaks in the United StatesD M Bell, E W Brink, J L Nitzkin, et al.
The Journal of Infectious Diseases|June 1, 1996
Hantavirus pulmonary syndrome: the first 100 US casesA S Khan, R F Khabbaz, L R Armstrong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2008
Rickettsia parkeri rickettsiosis and its clinical distinction from Rocky Mountain spotted feverChristopher D Paddock, Richard W Finley, Cynthia S Wright, et al.
Antiviral Therapy|March 21, 2000
Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study GroupL E Chapman, G J Mertz, C J Peters, et al.
Pageof 26